Pathophysiological role of IL-6 and IL-8 in the progression of prostate cancer and cachexia
Pathophysiological role of IL-6 and IL-8 in the progression of prostate cancer and cachexia
批准号:
10671494
负责人:
NAKASHIMA Jun
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 2001
中文摘要
在体外实验中,前列腺癌PC3、DU145、JCA1细胞株产生IL-6。IL-6可促进PCS细胞的生长。抗IL-6抗体对JCA1细胞生长有抑制作用。这些结果表明,IL-6是由前列腺癌细胞产生的,并调节前列腺癌细胞的生长。血清IL-6水平与前列腺癌的临床分期显著相关。肿瘤组织学与血清IL-6无明显相关性。血清IL-6水平[大于或等于]7pg/ml的患者血清PSA、LDH和ALP水平显著高于血清IL-6水平<1pg/ml的患者,且EOD与血清IL-6显著相关。血清IL-6[大于或等于]7pg/ml的患者的生存率显著低于血清IL-6和IL-6<7pg/ml的患者,多因素Cox比例风险模型分析显示,EOD和IL-6是影响预后的显著因素。提示血清IL-6水平与前列腺癌的侵袭性有关,是前列腺癌的重要预后因素。复发组患者血清肿瘤坏死因子活性高于初治组和缓解组。血清肿瘤坏死因子水平升高的患者血清总蛋白和白蛋白水平、血红蛋白水平、体重指数均显著低于未检测到肿瘤坏死因子水平的患者。血清白蛋白水平为3.5g/dl、血红蛋白水平为11.0g/dl、体重指数为21 kg/m2的患者的血清肿瘤坏死因子水平显著高于相应患者。血清肿瘤坏死因子水平升高的患者死亡率显著高于血清肿瘤坏死因子水平未检测到的患者。提示肿瘤坏死因子可能是前列腺癌患者恶病质复杂综合征的致病因素之一。
英文摘要
In in vitro experiments, prostate cancer cell lines, PC3, DU145, JCA1 produced IL-6. The growth of PCS cells was enhanced by IL-6. The growth of JCA1 cells was inhibited in the presence of anti IL-6 antibody. These results suggest that IL-6 is produced by prostate cancer cells and regulate the growth of prosate cancer cells. Serum IL-6 was significantly correlated with the clinical stage of prostate cancer. There was no significant association between tumor histology and serum IL-6. The serum PSA, LDH and ALP levels in the patients with serum IL-6 levels 【greater than or equal】 7 pg/ml were significantly higher than those in patients with serum IL-6 levels < 7 pg/ml. A significant association was found between EOD and serum IL-6. Patients with serum IL-6 【greater than or equal】 7 pg/ml had a significantly lower survival rate than those with serum IL-6 < 7 pg/ml. Multivariate Cox's proportional hazards model analysis showed that the significant prognostic factors were EOD and IL-6. These results indicate that the serum IL-6 level is asoociate with disease aggressiveness and a significant prognostic factor for prostate cancer. Serum TNF activity was elevated in patients with relapsed disease, when compared with the untreated patients and patients in remission. The serum total protein and albumin levels, hemoglobin levels, and body mass index of the patients with elevated serum TNF levels were significantly lower than those in patients with undetectable serum TNF levels. The serum TNF levels of patients with serum albumin levels of < 3.5 g/dl, hemoglobin levels of < 11.0 g/dl and a body mass index of < 21 kg/m2 were significantly higher than the values in their respective counterparts. Patients with elevated serum TNF levels had a significantly higher mortality rate than those with undetectable serum TNF levels. These findings suggest that TNF may be one of the factors contributing to the complex syndrome of cachexia in patients with prostate cancer.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Jun Nakashima et al.: "The value of γ-seminoprotein in combination with prostate specific antigen in detecting prostate cancer"Int J Urol. 6. 298-304 (1999)
Jun Nakashima 等人:“γ-精蛋白与前列腺特异性抗原结合在检测前列腺癌中的价值”Int J Urol. 6. 298-304 (1999)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Jun Nakashima, et al.: "Serum interleukin 6 as a prognostic factor in patients with prostate cancer."Clinical Cancer Research. 6. 2702-2706 (2000)
Jun Nakashima 等人:“血清白细胞介素 6 作为前列腺癌患者的预后因素。”临床癌症研究。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Treatment strategies of urological cancers through the regulation of inflammatory immune response by novel NFkappaB inhibitors
-
批准号:25462502
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.16万
-
财政年份:2013
-
负责人:NAKASHIMA Jun
-
依托单位:
Therapeutic strategy targeting NFκB-IL6 pathway against progression and paraneoplastic syndrome in prostate cancer
-
批准号:22591779
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.83万
-
财政年份:2010
-
负责人:NAKASHIMA Jun
-
依托单位:
Elucidation of pathophysiological significance of LIF and development of new treatment strategy in prostate cancer
-
批准号:14571522
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.11万
-
财政年份:2002
-
负责人:NAKASHIMA Jun
-
依托单位:
国内基金
海外基金
Aquaporin介导的严重创伤后Interleukin-6致血脑屏障通透性增加的分子机制研究
-
批准号:81801909
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2018
-
负责人:杨思明
-
依托单位:
Interleukin 6/gp130信号通路影响白癜风移植疗效的机制
-
批准号:81271758
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2012
-
负责人:许爱娥
-
依托单位: